AVITA Medical to Announce Second Quarter 2025 Financial Results
AVITA Medical (NASDAQ: RCEL) has scheduled its second quarter 2025 financial results announcement for Thursday, August 7, 2025, after U.S. market close. The company will host a conference call and webcast on the same day at 1:30 p.m. Pacific Time (August 8, 2025, at 6:30 a.m. Australian Eastern Standard Time).
Investors can access the live webcast through the Events & Presentations section on AVITA Medical's website. To join via telephone, participants must pre-register to receive dial-in details and a personal PIN. A replay will be available on the company's Investor Relations website after the event.
AVITA Medical (NASDAQ: RCEL) ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per giovedì 7 agosto 2025, dopo la chiusura del mercato statunitense. La società terrà una conference call e una webcast lo stesso giorno alle 13:30 ora del Pacifico (8 agosto 2025, alle 6:30 ora standard dell'Australia orientale).
Gli investitori potranno accedere alla diretta streaming tramite la sezione Eventi e Presentazioni sul sito web di AVITA Medical. Per partecipare telefonicamente, è necessario registrarsi in anticipo per ricevere i dettagli di accesso e un PIN personale. Una registrazione sarà disponibile sul sito web delle Relazioni con gli Investitori dopo l'evento.
AVITA Medical (NASDAQ: RCEL) ha programado el anuncio de sus resultados financieros del segundo trimestre de 2025 para el jueves 7 de agosto de 2025, después del cierre del mercado estadounidense. La compañía realizará una llamada en conferencia y una transmisión en vivo el mismo día a las 1:30 p.m., hora del Pacífico (8 de agosto de 2025, a las 6:30 a.m., hora estándar del este australiano).
Los inversores pueden acceder a la transmisión en vivo a través de la sección de Eventos y Presentaciones en el sitio web de AVITA Medical. Para unirse por teléfono, los participantes deben registrarse previamente para recibir los detalles de acceso y un PIN personal. Una repetición estará disponible en el sitio web de Relaciones con Inversores después del evento.
AVITA Medical (NASDAQ: RCEL)은 2025년 2분기 재무 실적 발표를 2025년 8월 7일 목요일 미국 시장 마감 후에 예정하고 있습니다. 회사는 같은 날 태평양 표준시 오후 1시 30분(2025년 8월 8일 호주 동부 표준시 오전 6시 30분)에 컨퍼런스 콜과 웹캐스트를 진행할 예정입니다.
투자자들은 AVITA Medical 웹사이트의 이벤트 및 프레젠테이션 섹션을 통해 라이브 웹캐스트에 접속할 수 있습니다. 전화로 참여하려면 사전에 등록하여 전화 접속 정보와 개인 PIN을 받아야 합니다. 이벤트 후 회사 투자자 관계 웹사이트에서 다시보기 서비스를 이용할 수 있습니다.
AVITA Medical (NASDAQ : RCEL) a programmé l'annonce de ses résultats financiers pour le deuxième trimestre 2025 le jeudi 7 août 2025, après la clôture du marché américain. La société organisera une conférence téléphonique et une webdiffusion le même jour à 13h30, heure du Pacifique (8 août 2025 à 6h30, heure normale de l'Est australien).
Les investisseurs peuvent accéder à la diffusion en direct via la section Événements et Présentations du site web d'AVITA Medical. Pour participer par téléphone, les participants doivent s'inscrire à l'avance afin de recevoir les détails d'accès et un code PIN personnel. Une rediffusion sera disponible sur le site des Relations Investisseurs après l'événement.
AVITA Medical (NASDAQ: RCEL) hat die Bekanntgabe der Finanzergebnisse für das zweite Quartal 2025 für Donnerstag, den 7. August 2025 nach Marktschluss in den USA geplant. Das Unternehmen wird am selben Tag um 13:30 Uhr Pazifischer Zeit (8. August 2025, 6:30 Uhr Australische Oststandardzeit) eine Telefonkonferenz und einen Webcast veranstalten.
Investoren können den Live-Webcast über den Bereich Veranstaltungen & Präsentationen auf der Website von AVITA Medical verfolgen. Um telefonisch teilzunehmen, müssen sich die Teilnehmer vorab registrieren, um Einwahldaten und eine persönliche PIN zu erhalten. Eine Aufzeichnung wird nach der Veranstaltung auf der Investor-Relations-Website des Unternehmens verfügbar sein.
- None.
- None.
VALENCIA, Calif. and MELBOURNE, Australia, July 28, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced that it will report its second quarter 2025 financial results after the close of the U.S. financial markets on Thursday, August 7, 2025. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, August 8, 2025, at 6:30 a.m. Australian Eastern Standard Time) to discuss its financial results and recent business highlights.
The live webcast will be accessible under the Events & Presentations section of the AVITA Medical website at ir.avitamedical.com. To participate by telephone, please register in advance to receive dial-in details and a personal PIN using the following link: https://register-conf.media-server.com/register/BI2760d86b79a7479f830f23dd916bd991 A replay of the webcast will be available shortly after the live event on the Investor Relations website.
About AVITA Medical, Inc.
AVITA Medical® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is the RECELL® System, approved by the FDA for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin™ Cells, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the exclusive rights to manufacture, market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix, and the exclusive rights to market, sell, and distribute Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix.
In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including burns and full-thickness skin defects. The RECELL System, excluding RECELL GO®, is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan.
To learn more, visit www.avitamedical.com.
Investor & Media Contact:
Ben Atkins
Phone +1-805 341 1571
investor@avitamedical.com
media@avitamedical.com
Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.
